ABSTRACT

Isotope tracer methodology provides a quantitative framework for investigating metabolic flux, substrate turnover and pathway compartmentalization in vivo. Tracer approaches enable dynamic examination of biochemical systems with minimal physiological perturbation, this can be achieved by harnessing the mass distinction and chemical equivalence of stable (e.g., ¹³C, ¹⁵N, ²H) and radioactive (e.g., ¹⁴C, ³H, ¹⁸F) isotopes. This review synthesizes the physicochemical basis of isotopic labeling, tracer dilution principles and nuclear decay mechanisms underlying scintillation detection and positron emission tomography (PET). Emphasis is placed on isotopologue distribution analysis using mass spectrometry (MS) (e.g. natural abundance correction, isotopic impurity adjustment, and resolution of spectral overlap: analytical considerations essential for accurate metabolic flux analysis). Applications in biomolecule (glucose, lipid, protein and glutamine) metabolism are examined, as well as ¹⁸F-fluorodeoxyglucose PET and hybrid PET/computed tomography (translational imaging strategies). The safety, sensitivity, and spatial resolution levels of stable and radioactive tracers are comparatively evaluated. Critical methodological limitations (such as tracer recycling, steady-state assumptions, compartmental modeling limitations, and cost considerations) are addressed to define its limits in terms of interpretation. Emerging advances in multi-isotope tracing, high-resolution MS platforms, and integrated systems level modeling are discussed as future directions. When applied with rigorous quantitative discipline and transparent analytical correction, isotope tracer methodologies remain essential tools for revealing metabolic regulation, disease pathophysiology and therapeutic response.

KEYWORDS

Isotope tracers; ¹³C metabolic flux analysis; stable isotopes; PET imaging; systems metabolism; pharmacokinetics; isotope-resolved metabolomics

REFERENCES

1) American Diabetes Association. (2014). Diagnosis and classification of diabetes mellitus. Diabetes Care, 37(Supplement 1), S81–S90. https://doi.org/10.2337/dc14-S081
2) American Diabetes Association. (2023). Classification and diagnosis of diabetes: Standards of care in diabetes—2023. Diabetes Care, 46(Supplement_1), S19–S40. https://doi.org/10.2337/dc23-S002
3) American Society for Hybrid, Molecular and Translational Imaging (2024). ESR essentials: Staging and restaging with FDG-PET/CT in oncology—Practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. European Radiology. https://link.springer.com/article/10.1007/s00330-024-11094-8 (PubMed)
4) Antoniewicz, M. R. (2015). Methods and advances in metabolic flux analysis: A mini-review. Journal of Industrial Microbiology & Biotechnology, 42(3), 317-325. https://doi.org/10.1007/s10295-015-1585-x
5) Ayeni, A., Evbuomwan, O., & Vangu, M.-D. T. W. (2025). The role of ¹⁸F-FDG PET/CT in monitoring of therapy response in lung cancer. Seminars in Nuclear Medicine, 55(2), 175–189. https://doi.org/10.1053/j.semnuclmed.2025.02.002
6) Barrie, A., & Prosser, S. J. (1996). Automated analysis of light-element stable isotopes by isotope ratio mass spectrometry. In T. W. Boutton & S. Yamasaki (Eds.), Mass spectrometry of soils (pp. 1-46). Marcel Dekker.
7) Basu, R., Chandramouli, V., Dicke, B., Landau, B., & Rizza, R. (2006). Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes, 54(7), 1942-1948. https://doi.org/10.2337/diabetes.54.7.1942
8) Bier, D. M. (1987). The use of stable isotopes in metabolic investigation. Baillière’s Clinical Endocrinology and Metabolism, 1(4), 817-836. https://doi.org/10.1016/s0950-351x(87)80007-1
9) Bier, D. M. (1997). Stable isotopes in metabolic research: Applications and perspectives. The Journal of Clinical Investigation, 99(6), 1133–1137. https://doi.org/10.1172/JCI119270
10) Brooks, D. J. (2010). Imaging approaches to Parkinson disease. Journal of Nuclear Medicine, 51(4), 596-609. https://doi.org/10.2967/jnumed.108.059998
11) Burd, N. A., West, D. W., Moore, D. R., Atherton, P. J., Staples, A. W., Prior, T., Tang, J. E., Rennie, M. J., Baker, S. K., & Phillips, S. M. (2013). Enhanced amino acid sensitivity of myofibrillar protein synthesis persists for up to 24 h after resistance exercise in young men. Journal of Nutrition, 143(4), 876-880. https://doi.org/10.3945/jn.110.135038
12) Busch, R., Kim, Y. K., Neese, R. A., Schade-Serin, V., Collins, M., Awada, M., Gardner, J. L., Beysen, C., Marino, M. E., Misell, L. M., & Hellerstein, M. K. (2006). Measurement of protein turnover rates by heavy water labeling of nonessential amino acids. Biochimica et Biophysica Acta, 1760(5), 730-744. https://doi.org/10.1016/j.bbagen.2005.12.023
13) Calderoni, L., Giovanella, L., & Fanti, S. (2024). Endocrinology application of molecular imaging: Current role of PET/CT. Journal of Endocrinological Investigation, 47(10), 2383–2396. https://doi.org/10.1007/s40618-024-02400-8
14) Chace, D. H. (2001). Mass spectrometry in the clinical laboratory. Chemical Reviews, 101(2), 445-478. https://doi.org/10.1021/cr990077+
15) Cherry, S. R., Sorenson, J. A., & Phelps, M. E. (2012). Physics in nuclear medicine (4th ed.). Elsevier Saunders.
16) Cherry, S. R., Sorenson, J. A., & Phelps, M. E. (2021). Physics in nuclear medicine (5th ed.). Elsevier.
17) Calderoni, L., Giovanella, L., & Fanti, S. (2024). Endocrinology applications of molecular imaging: Current role of PET/CT. Journal of Endocrinological Investigation, 47(10), 2383–2396. https://doi.org/10.1007/s40618-024-02400-8
18) Cobelli, C., Toffolo, G., Bier, D. M., & Nosadini, R. (1987). Models to interpret kinetic data in stable isotope tracer studies. American Journal of Physiology-Endocrinology and Metabolism, 253(5), E551-E564. https://doi.org/10.1152/ajpendo.1987.253.5.E551
19) Consoli, A., Nurjhan, N., Capani, F., & Gerich, J. (1989). Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes, 38(5), 550-557. https://doi.org/10.2337/diab.38.5.550
20) DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique: A method for quantifying insulin secretion and resistance. American Journal of Physiology-Endocrinology and Metabolism, 237(3), E214-E223. https://doi.org/10.1152/ajpendo.1979.237.3.E214
21) Des Rosiers, C., Fernandez, C. A., David, F., & Brunengraber, H. (1994). Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver: Evidence from isotopomer analysis of citric acid cycle intermediates. Journal of Biological Chemistry, 269(44), 27179-27182. https://doi.org/10.1016/S0021-9258(18)46979-9
22) Dimitrakopoulou-Strauss, A., Pan, L., & Sachpekidis, C. (2024). Non-[¹⁸F]FDG PET-radiopharmaceuticals in oncology. Pharmaceuticals, 17(12), 1641. https://doi.org/10.3390/ph17121641
23) Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation, 115(5), 1343-1351. https://doi.org/10.1172/JCI23621
24) European Society for Hybrid, Molecular and Translational Imaging. (2024). ESR essentials: Staging and restaging with FDG-PET/CT in oncology-Practice recommendations. European Radiology, 34(11), 7432-7445. https://doi.org/10.1007/s00330-024-11094-8
25) Gambhir, S. S. (2002). Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer, 2(9), 683-693. https://doi.org/10.1038/nrc882
26) Giacomini, K. M., Huang, S. M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., … Zhang, L. (2010). Membrane transporters in drug development. Nature Reviews Drug Discovery, 9(3), 215-236. https://doi.org/10.1038/nrd3028
27) Goodman, K. J., & Brenna, J. T. (1992). High sensitivity tracer detection using high-precision gas chromatography-combustion isotope ratio mass spectrometry and highly enriched [U-¹³C]-labeled precursors. Analytical Chemistry, 64(11), 1088-1095. https://doi.org/10.1021/ac00034a004
28) Hall, K. D. (2012). Energy balance and its components: Implications for body weight regulation. The American Journal of Clinical Nutrition, 95(4), 989–994. https://doi.org/10.3945/ajcn.112.036350
29) Hall, K. D., & Guo, J. (2017). Obesity energetics: Body weight regulation and the effects of diet composition. Gastroenterology, 152(7), 1718–1727.e3. https://doi.org/10.1053/j.gastro.2017.01.052
30) Hellerstein, M. K. (1999). Measurement of lipid synthesis and turnover in humans using stable isotopes. Journal of Lipid Research, 40(3), 433–456. https://doi.org/10.1016/S0022-2275(20)32139-4
31) Helm, M., & Motorin, Y. (2017). Detecting RNA modifications in the epitranscriptome: Predict and validate. Nature Reviews Genetics, 18(5), 275-291. https://doi.org/10.1038/nrg.2016.169
32) Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., Wodzak, M., Klimko, C., McMillan, E., Butt, Y., Ni, M., Oliver, D., Torrealba, J., Malloy, C. R., Kernstine, K., … DeBerardinis, R. J. (2016). Metabolic heterogeneity in human lung tumors. Cell, 164(4), 681-694. https://doi.org/10.1016/j.cell.2015.12.034
33) Herholz, K. (2010). Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease. Expert Review of Neurotherapeutics, 10(11), 1667-1673. https://doi.org/10.1586/ern.10.136
34) Hop, C. E., Wang, Z., Chen, Q., & Kwei, G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. Journal of Pharmaceutical Sciences, 87(7), 901-903. https://doi.org/10.1021/js970486q
35) Huang, S. C. (2000). Anatomy of SUV. Nuclear Medicine and Biology, 27(7), 643-646. https://doi.org/10.1016/S0969-8051(00)00155-4
36) Huang, S. M., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Al-Habet, S. A., Baweja, R. K., Burckart, G. J., Chung, S., Colangelo, P., Frucht, D., Green, M. D., Hepp, P., Karnaukhova, E., Ko, H. S., Lee, J. I., Marroum, P. J., … Throckmorton, D. C. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. Journal of Clinical Pharmacology, 48(6), 662-670. https://doi.org/10.1177/0091270007312153
37) International Atomic Energy Agency. (2021). Radiation safety of radionuclide sources and tracers: Fundamentals and standards. Vienna Austria: IAEA.
38) International Atomic Energy Agency. (2022). Doubly labelled water method for measuring energy expenditure: Human health series. IAEA.
39) International Conference on Harmonisation. (1996). ICH harmonised tripartite guideline: Guideline for good clinical practice E6(R1). https://database.ich.org/sites/default/files/E6_R1_Guideline.pdf
40) Isin, E. M., Elmore, C. S., Nilsson, G. N., Thompson, R. A., & Weidolf, L. (2012). Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chemical Research in Toxicology, 25(3), 532-542. https://doi.org/10.1021/tx2005212
41) Jang C, Chen, L., & Rabinowitz, J. D. (2022). Metabolomics and isotope tracing. Cell, 185(2), 247–267. https://doi.org/10.1016/j.cell.2021.12.010
42) Kelleher, J. K., & Masterson, T. M. (1992). Model equations for condensation biosynthesis using stable isotopes and radioisotopes. American Journal of Physiology-Endocrinology and Metabolism, 262(1), E118-E125. https://doi.org/10.1152/ajpendo.1992.262.1.E118
43) Khalil, M. M., Tremoleda, J. L., Bayomy, T. B., & Gsell, W. (2011). Molecular SPECT imaging: An overview. International Journal of Molecular Imaging, 2011, Article 796025. https://doi.org/10.1155/2011/796025
44) Khojasteh, S. C., Oishi, S., & Nelson, S. D. (2011). Metabolism and toxicity of menthofuran in rat liver slices and in rats. Chemical Research in Toxicology, 24(12), 2123-2133. https://doi.org/10.1021/tx200291b
45) Kim, S. Y., Chung, H. W., So, Y., Lee, M. H., & Lee, E. J. (2024). Recent updates of PET in lymphoma: FDG and beyond. Biomedicines, 12(11), 2485. https://doi.org/10.3390/biomedicines12112485
46) Klein, S., & Wolfe, R. R. (2022). Stable isotopes in clinical metabolic research: Applications in human physiology and disease. The American Journal of Clinical Nutrition, 115(6), 1505–1516. https://doi.org/10.1093/ajcn/nqac044
47) Knoll, G. F. (2010). Radiation detection and measurement (4th ed.). John Wiley & Sons.
48) Landau, B. R., Wahren, J., Chandramouli, V., Schumann, W. C., Ekberg, K., & Kalhan, S. C. (1996). Contributions of gluconeogenesis to glucose production in the fasted state. Journal of Clinical Investigation, 98(2), 378-385. https://doi.org/10.1172/JCI118803
49) L’Annunziata, M. F. (2012). Handbook of radioactivity analysis (3rd ed.). Academic Press.
50) Lappin, G., & Temple, R. (2006). Radiotracers in drug development. CRC Press.
51) Lappin, G., Kuhnz, W., Jochemsen, R., Kneer, J., Chaudhary, A., Oosterhuis, B., Drijfhout, W. J., Rowland, M., & Garner, R. C. (2005). Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clinical Pharmacology and Therapeutics, 77(3), 203-215. https://doi.org/10.1016/j.clpt.2004.11.001
52) Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., Gan, L. S., LeCluyse, E. L., & Parkinson, A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition, 31(4), 421–431. https://doi.org/10.1124/dmd.31.4.421
53) Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992). Increased rate of gluconeogenesis in type II diabetes mellitus: A ¹³C nuclear magnetic resonance study. Journal of Clinical Investigation, 90(4), 1323-1327. https://doi.org/10.1172/JCI115997
54) Meselson, M., & Stahl, F. W. (1958). The replication of DNA in Escherichia coli. Proceedings of the National Academy of Sciences, 44(7), 671-682. https://doi.org/10.1073/pnas.44.7.671
55) Mettler, F. A., Huda, W., Yoshizumi, T. T., & Mahesh, M. (2008). Effective doses in radiology and diagnostic nuclear medicine: A catalog. Radiology, 248(1), 254-263. https://doi.org/10.1148/radiol.2481071451
56) Nelson, D. L., & Cox, M. M. (2017). Lehninger principles of biochemistry (7th ed.). New York, NY: W. H. Freeman. https://www.macmillanlearning.com/college/us/product/Lehninger-Principles-of-Biochemistry/p/1319108245
57) Nobel Prize Outreach. (2023). George de Hevesy—Biographical. https://www.nobelprize.org/prizes/chemistry/1943/hevesy/biographical/
58) Obach, R. S. (1999). Prediction of human clearance of drugs from in vitro data. Drug Metabolism and Disposition, 27(11), 1350–1359. https://dmd.aspetjournals.org/content/27/11/1350
59) Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2008). Glucuronidation converts xenobiotics to toxic products. Chemical Research in Toxicology, 21(4), 760–767. https://doi.org/10.1021/tx7004059
60) Olkkola, K. T., Ahonen, J., & Neuvonen, P. J. (1993). The effects of enzyme inhibitors on drug metabolism. Clinical Pharmacokinetics, 24(2), 105–121. https://doi.org/10.2165/00003088-199324020-00002
61) Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular & Cellular Proteomics, 1(5), 376-386. https://doi.org/10.1074/mcp.M200025-MCP200
62) Patterson, B. W., Carraro, F., & Wolfe, R. R. (1993). Measurement of ¹⁵N enrichment in multiple amino acids and urea in a single analysis by gas chromatography/mass spectrometry. Biological Mass Spectrometry, 22(9), 518-523. https://doi.org/10.1002/bms.1200220908
63) Patterson, B. W., Zhao, G., Elias, N., Hachey, D. L., & Klein, S. (2002). Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. Journal of Lipid Research, 43(5), 720–727. https://doi.org/10.1016/S0022-2275(20)30467-X
64) Penner, N., Klunk, L. J., & Prakash, C. (2009). Human radiolabeled mass balance studies: Objectives, utilities and limitations. Biopharmaceutics & Drug Disposition, 30(4), 185–203. https://doi.org/10.1002/bdd.659
65) Phelps, M. E. (2000). Positron emission tomography provides molecular imaging of biological processes. Proceedings of the National Academy of Sciences, 97(16), 9226-9233. https://doi.org/10.1073/pnas.97.16.9226
66) Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C., Sokoloff, L., & Kuhl, D. E. (1979). Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method. Annals of Neurology, 6(5), 371-388. https://doi.org/10.1002/ana.410060502
67) Pichler, B. J., Kolb, A., Nägele, T., & Schlemmer, H. P. (2010). PET/MRI: Paving the way for the next generation of clinical multimodality imaging applications. Journal of Nuclear Medicine, 51(3), 333-336. https://doi.org/10.2967/jnumed.109.061853
68) Piel, M., Vernaleken, I., & Rösch, F. (2014). Positron emission tomography in CNS drug discovery and drug monitoring. Journal of Medicinal Chemistry, 57(22), 9232-9258. https://doi.org/10.1021/jm5001858
69) Roberts, M. S., Magnusson, B. M., Burczynski, F. J., & Weiss, M. (2002). Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics, 41(10), 751-790. https://doi.org/10.2165/00003088-200241100-00005
70) Roffey, S. J., Obach, R. S., Gedge, J. I., & Smith, D. A. (2007). What is the objective of mass balance studies in humans? Drug Metabolism Reviews, 39(1), 17–43. https://doi.org/10.1080/03602530601032238
71) Rowland, M., & Tozer, T. N. (2011). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (4th ed.). Philadelphia, PA: Lippincott Williams & Wilkins.
72) Schelbert, H. R., Beanlands, R., Bengel, F., Knuuti, J., Di Carli, M., Machac, J., & Patterson, R. (2003). PET myocardial perfusion and glucose metabolism imaging: Part 2—Guidelines for interpretation and reporting. Journal of Nuclear Cardiology, 10(5), 557-571. https://doi.org/10.1016/S1071-3581(03)00666-3
73) Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011). Global quantification of mammalian gene expression control. Nature, 473(7347), 337-342. https://doi.org/10.1038/nature10098
74) Schwochau, K. (1994). Technetium radiopharmaceuticals—Fundamentals, synthesis, structure, and development. Angewandte Chemie International Edition in English, 33(22), 2258-2267. https://doi.org/10.1002/anie.199422581
75) Shipkova, M., & Wieland, E. (2001). Glucuronidation in therapeutic drug monitoring. Clinical Chimica Acta, 313(1–2), 43–57. https://doi.org/10.1016/S0009-8981(01)00605-8
76) Solon, E. G., Kraus, A., & Schmitz, R. (2010). Methods for assessing tissue distribution of drugs. Current Drug Metabolism, 11(9), 798–809. https://doi.org/10.2174/138920010793175895
77) Steele, R. (1959). Influences of glucose loading and of injected insulin on hepatic glucose output. Annals of the New York Academy of Sciences, 82(2), 420-430. https://doi.org/10.1111/j.1749-6632.1959.tb44923.x
78) Streetman, D. S., Bertino, J. S., Jr., & Nafziger, A. N. (2000). Phenotyping of drug-metabolizing enzymes in humans. Clinical Pharmacokinetics, 38(5), 347–365. https://doi.org/10.2165/00003088-200038050-00002
79) Timmins, P. (2014). The utility of mass balance studies in drug development. Drug Metabolism and Disposition, 42(1), 3–7. https://doi.org/10.1124/dmd.113.053231
80) U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies. Rockville, MD: Author. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents
81) Wolfe, R. R. (1992). Radioactive and stable isotope tracers in biomedicine: Principles and practice of kinetic analysis. Wiley-Liss.
82) Wolfe, R. R., & Chinkes, D. L. (2005). Isotope tracers in metabolic research: Principles and practice of kinetic analysis (2nd ed.). John Wiley & Sons.
83) Wolfe, R. R., & Chinkes, D. L. (2017). Isotope tracers in metabolic research: Principles and practice of kinetic analysis (2nd ed.). Wiley.
84) Wolfe, R. R., Chinkes, D. L., & Ferrando, A. A. (2020). Isotope tracers in metabolic research: Applications in nutrition and human disease. Clinical Nutrition, 39(3), 631–646. https://doi.org/10.1016/j.clnu.2019.09.020
85) Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007

Cite this article 

Tasi’u, U. M., Ifeyinwa, U. D., Perpetua, N. C., Mu’azu, I., Onyebuchi, U. T., Valentine, O. U., Godswill, N. C., & Usman, I. Y. (2026). Quantitative Isotope Tracer Methodologies for System-Level Metabolic Flux Analysis and Clinical Translation. INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, 5(7), 672-694. https://doi.org/10.58806/ijhmr.2026.v5i7n15